Aurora Cannabis Reveals Latest Product Innovations: Ultra-High Potency Indicas And Strains For Veterans
Aurora Cannabis Reveals Latest Product Innovations: Ultra-High Potency Indicas And Strains For Veterans
"As a company committed to leading the way in terms of cannabis innovation, we are dedicated to putting patients first by harnessing the innovative solutions developed by our top researchers at Aurora Coast, our unique global research facility," Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB), announced on Tuesday developments in cannabis science from Aurora's research and genetics facility, Aurora Coast.
奥罗拉大麻公司（纳斯达克股票代码：ACB）（多伦多证券交易所股票代码：ACB）周二宣布了奥罗拉研究和遗传机构奥罗拉海岸在大麻科学方面的进展。
The latest innovations from the Canadian medical cannabis giant include:
这家加拿大医用大麻巨头的最新创新包括：
- Aurora | CBD Varius (1g, 510 Cartridge);
- MedReleaf (Strains For Heroes) | Esprit De Corps (5g and 15g); a premium sativa (THC: 20-29%, CBD: 0-1%), developed under the Strains For Heroes initiative by Aurora with direct feedback from Veteran patients;
- MedReleaf | Sedamen (1g, 510 Cartridge) in a higher THC format;
- MedReleaf | Noculus (5g and 15g); an ultra-high potency indica, featuring THC levels between 25-31% and CBD content from 0-1%; and
- WMMC | Seasonal Stash – Frosted Alpine (10g); a limited-grown hybrid strain (THC: 24-30%; CBD: 0-1%).
- Aurora | CBD Varius（1g，510 个墨盒）；
- MedreLeaf（英雄菌株）| Esprit De Corps（5g和15g）；一种优质的苜蓿（四氢大麻酚：20-29％，CBD：0-1％），在Aurora的Strains For Heroes计划下开发，得到了退伍军人的直接反馈；
- MedreLeaf | 四氢大麻酚格式的 Sedamen（1g，510 墨盒）；
- MedreLeaf | Noculus（5g 和 15g）；一种超高效的印度草，四氢大麻酚含量介于 25-31% 之间，CBD 含量在 0-1% 之间；以及
- WMMC | 季节性藏匿物 — Frosted Alpine（10g）；限量种植的杂交菌株（四氢大麻酚：24-30%；CBD：0-1%）。
Read Also: Aurora Cannabis Launches Innovative THC Oil Products In Australia To Meet Diverse Patient Needs
另请阅读：Aurora Cannabis在澳大利亚推出创新的四氢大麻酚油产品，以满足不同的患者需求
- Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. If you're serious about the business, you can't afford to miss out.
- 每天在收件箱中免费获取Benzinga的独家分析以及有关大麻行业和市场的热门新闻。在这里订阅我们的时事通讯。如果你认真对待这项业务，就不能错过这个机会。
"As a company committed to leading the way in terms of cannabis innovation, we are dedicated to putting patients first by harnessing the innovative solutions developed by our top researchers at Aurora Coast, our unique global research facility," Lana Culley, vice president of science and innovation at Aurora. "We strive to continuously raise the bar on product superiority and overall user experience so that we can deliver on our mission of providing patients with access to the very best medical cannabis."
奥罗拉科学与创新副总裁拉娜·库利说：“作为一家致力于在大麻创新方面处于领先地位的公司，我们致力于利用我们独特的全球研究机构奥罗拉海岸的顶尖研究人员开发的创新解决方案，将患者放在第一位。”“我们努力不断提高产品优势和整体用户体验的标准，以便我们能够实现为患者提供最佳医用大麻的使命。”
The latest update from Aurora comes on the heels of its recently revealed lineup of innovations from Greybeard, San Rafael '71 and Tasty's brands for Canadian consumers.
Aurora的最新更新是在其最近为加拿大消费者公布的Greybeard、San Rafael '71和Tasty's品牌的创新产品系列之后发布的。
Aurora reported its second quarter financial results, showing revenue of CA$81.1 million ($58.3 million), up from CA$63.1 million in the same period last year.
Aurora公布了其第二季度财务业绩，收入为8,110万加元（合5,830万美元），高于去年同期的6,310万加元。
The company attributed the 29% increase from the prior period to 41% growth in its global medical cannabis business and 21% growth in its plant propagation business, slightly offset by lower quarterly revenue in its consumer cannabis business.
该公司将较上期增长29％归因于其全球医用大麻业务增长41％，植物繁殖业务增长21％，但消费大麻业务的季度收入下降略有抵消。
- UK Medical Cannabis Market Gets Boost With Aurora And Script Assist Collaboration
- Aurora和Script Assist的合作推动了英国医用大麻市场的发展
ACB Price Action
ACB 价格走势
Aurora's shares traded 3.28% lower at $4.42 per share at the time of writing on Tuesday morning.
在周二上午撰写本文时，Aurora的股价下跌3.28％，至每股4.42美元。